By Ben Glickman
Rocket Pharmaceuticals said on Tuesday that it had reached alignment with the U.S. Food and Drug Administration on a trial for its treatment for Danon disease. The company’s study, with endpoints evaluated after 12 months, will support accelerated approval of the treatment by the FDA. Shares rose 27%, to $19.40, after-hours.
KULR Technology Group announced it was planning an underwritten public offering of common stock in order to pay down an outstanding balance owed under a credit facility. The sustainable energy management company also will use the proceeds for general corporate purposes and working capital. Shares drop 23%, to 45 cents, after-hours, below their 52-week low.
Evolution Petroleum reported that its revenue dropped sharply in the fiscal fourth quarter. The company broke even on a per-share basis after selling lower volumes of oil and natural gas at lower realized prices. Shares fall 13%, to $7.72.
Write to Ben Glickman at ben.glickman@wsj.com
Read the full article here